Azilect Slows Progression Of Parkinson's Disease

Armen Hareyan's picture
Advertisement

Parkinson's disease progression slows down in phase III clinical study of ADAGIO that used Azilect 1mg tablets.

Lundbeck's partner Teva Pharmaceutical Industries Ltd. has today announced the successful completion of ADAGIO, the phase III trial designed to demonstrate that Azilect

Advertisement